Post-Transplant Lymphoproliferative Disorder Clinical Trials in Columbus, Ohio
3 recruitingColumbus, Ohio
Showing 1–3 of 3 trials
Recruiting
Phase 1
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
EBV-Related Lymphoproliferative DisorderPost-Transplant Lymphoproliferative DisorderChronic Kidney Disease Stage 5+2 more
Ohio State University Comprehensive Cancer Center55 enrolled1 locationNCT06741072
Recruiting
Phase 2
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Timothy Voorhees28 enrolled4 locationsNCT05786040
Recruiting
Phase 1
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more
Timothy Voorhees26 enrolled2 locationsNCT06672705